Results 91 to 100 of about 6,245 (194)

Development of a Novel Machine Learning Method for Estimation of Life‐Long Chronic Disease Progression and Its Application to Type 2 Diabetes

Clinical and Translational Science
Individual predictions of long‐term chronic disease progression from data of limited duration provide valuable insights into estimating patient outcomes and therapeutic needs.
Yamato Sano, Ryota Jin, Hideki Yoshioka, Yuki Nakazato, Hiromi Sato, Akihiro Hisaka   +5 more
doaj   +1 more source

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +1 more source

Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach

Clinical and Translational Science
Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible ...
Ahsan Rizwan, Hugh Giovinazzo, Tian Yu, Yuying Gao, Kun Wang, Fengyan Xu, Ya Wan, Jun Wang, Srikumar Sahasranaman, Marcia Campbell, Patrick Schnell, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha   +13 more
doaj   +1 more source

Pharmacometrics and/or Systems Pharmacology [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2019
openaire   +3 more sources

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +1 more source

Response to “mixed‐effects models and the drug titration paradox”

CPT: Pharmacometrics & Systems Pharmacology, 2023
Niels Rode Kristensen, Henrik Agersø
doaj   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
wiley   +1 more source

OpenPMX Software for Nonlinear Mixed-Effect Models in Pharmacometrics: Precision Compared With NONMEM First-Order Conditional Estimation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Eleveld DJ, Koomen JV, Stevens J, Colin PJ, Struys MMRF.   +4 more
europepmc   +1 more source

Pioneering pharmacometrics practice in Korea: an eight-year retrospective analysis of 192 projects from the first dedicated service organization (2016-2024). [PDF]

Transl Clin Pharmacol
Lee SJ, Bae SH, Park J, Hong Y, Jun Y, Han S, Yim DS.   +6 more
europepmc   +1 more source

Evaluating LLM Integration in Pharmacometrics Through a Software Development Perspective. [PDF]

J Pediatr Pharmacol Ther
Barrett K, Callisto SP.
europepmc   +1 more source